Leerink Swann Raises PT on Santarus (SNTS)

March 5, 2013 11:34 AM EST Send to a Friend
Get Alerts SNTS Hot Sheet
Price: $31.96 --0%

Rating Summary:
    3 Buy, 3 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 24 | Down: 13 | New: 40
Trade SNTS Now!
Join SI Premium – FREE
Leerink Swann today reiterated an Outperform on Santarus (NASDAQ: SNTS) and raised its price target to $17 to $18 (from $15 to $16). Yesterday Santarus reported Q4 results.

Commenting on the news, analyst Jason M. Gerberry said, "We are encouraged by the strength of Zegerid---which had higher-than-expected AG volume & pricing---and mgmt's positive commentary on the launch of Uceris---initial feedback from managed care plans has been positive noting pricing is viewed favorably in context of other second line options such as biologic therapy, and mgmt is less concerned about prior authorizations."

For an analyst ratings summary and ratings history on Santarus (NASDAQ: SNTS) click here. For more ratings news on Santarus click here.

Shares of Santarus closed at $13.80 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS View, Analyst PT Change

Add Your Comment